268 related articles for article (PubMed ID: 32060401)
21. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1.
Hong YS; Hong SW; Kim SM; Jin DH; Shin JS; Yoon DH; Kim KP; Lee JL; Heo DS; Lee JS; Kim TW
Int J Oncol; 2012 Jul; 41(1):76-82. PubMed ID: 22552540
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
23. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
Tai YT; Mayes PA; Acharya C; Zhong MY; Cea M; Cagnetta A; Craigen J; Yates J; Gliddon L; Fieles W; Hoang B; Tunstead J; Christie AL; Kung AL; Richardson P; Munshi NC; Anderson KC
Blood; 2014 May; 123(20):3128-38. PubMed ID: 24569262
[TBL] [Abstract][Full Text] [Related]
24. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
Yu T; Chaganty B; Lin L; Xing L; Ramakrishnan B; Wen K; Hsieh PA; Wollacott A; Viswanathan K; Adari H; Cho SF; Li Y; Chen H; Yang W; Xu Y; An G; Qiu L; Munshi N; Babcock G; Shriver Z; Myette JR; Anderson KC; Tai YT
Blood Cancer J; 2020 Nov; 10(11):110. PubMed ID: 33149123
[TBL] [Abstract][Full Text] [Related]
25. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
26. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
27. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
29. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus.
E X; Pickering MT; Debatis M; Castillo J; Lagadinos A; Wang S; Lu S; Kowalik TF
PLoS Pathog; 2011 May; 7(5):e1001342. PubMed ID: 21589897
[TBL] [Abstract][Full Text] [Related]
30. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Chauhan D; Li G; Podar K; Hideshima T; Shringarpure R; Catley L; Mitsiades C; Munshi N; Tai YT; Suh N; Gribble GW; Honda T; Schlossman R; Richardson P; Sporn MB; Anderson KC
Blood; 2004 Apr; 103(8):3158-66. PubMed ID: 15070698
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
33. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
Kinneer K; Flynn M; Thomas SB; Meekin J; Varkey R; Xiao X; Zhong H; Breen S; Hynes PG; Fleming R; Bezabeh B; Chen CT; Wetzel L; Chen R; Dimasi N; Tai YT; Anderson KC; Herbst R; Howard PW; Hurt EM; Tice DA
Leukemia; 2019 Mar; 33(3):766-771. PubMed ID: 30315237
[No Abstract] [Full Text] [Related]
34. ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies.
Botrugno OA; Bianchessi S; Zambroni D; Frenquelli M; Belloni D; Bongiovanni L; Girlanda S; Di Terlizzi S; Ferrarini M; Ferrero E; Ponzoni M; Marcatti M; Tonon G
Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054085
[TBL] [Abstract][Full Text] [Related]
35. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
Soriani A; Zingoni A; Cerboni C; Iannitto ML; Ricciardi MR; Di Gialleonardo V; Cippitelli M; Fionda C; Petrucci MT; Guarini A; Foà R; Santoni A
Blood; 2009 Apr; 113(15):3503-11. PubMed ID: 19098271
[TBL] [Abstract][Full Text] [Related]
36. DNA damage checkpoint kinases in cancer.
Smith HL; Southgate H; Tweddle DA; Curtin NJ
Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
[TBL] [Abstract][Full Text] [Related]
37. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
[TBL] [Abstract][Full Text] [Related]
38. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.
Landau HJ; McNeely SC; Nair JS; Comenzo RL; Asai T; Friedman H; Jhanwar SC; Nimer SD; Schwartz GK
Mol Cancer Ther; 2012 Aug; 11(8):1781-8. PubMed ID: 22653969
[TBL] [Abstract][Full Text] [Related]
39. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
40. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
Xiao G; Kue P; Bhosle R; Bargonetti J
Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]